The pharmaceutical company responsible for manufacturing OxyContin will cease operations and transform into a public-focused organization as a comprehensive legal agreement involving thousands of opioid lawsuits becomes active this Friday.
This agreement represents one of the most significant in a string of legal resolutions addressing the devastating impact of opioid addiction in recent years. The case has drawn particular attention because many experts trace the origins of America’s opioid crisis to the aggressive marketing campaigns surrounding OxyContin, a potent prescription pain medication that entered the market in 1996.
Federal statistics indicate that opioid overdoses have claimed more than 500,000 American lives since 1999. The crisis initially stemmed from prescription painkillers, later shifted to heroin, and has now reached its deadliest phase with fentanyl-related deaths.
The Purdue agreement mandates a minimum payment of $7.4 billion. The majority of these funds—no less than $6.5 billion—will come directly from Sackler family members who previously held ownership of the company. The family relinquished control of the pharmaceutical manufacturer before its 2019 bankruptcy filing and has surrendered all ownership stakes. The settlement creates Knoa Pharma as Purdue’s replacement, featuring a state-appointed board dedicated to combating the opioid epidemic.
Analysis from the Opioid Settlement Tracker shows that total opioid litigation settlements have reached an estimated $50 billion since 2019. Companies that have reached agreements with state and local authorities include drug manufacturers, distribution companies, pharmacy chains, and consulting firms. Settlement terms typically require that most funds address epidemic-related issues.
Purdue’s settlement payments will be distributed over an 18-year period, with larger amounts scheduled for the initial years.
The Department of Justice investigation into Purdue resulted in criminal charges against three individuals and a corporate guilty plea by the company.
In 2024, five Supreme Court justices rejected an earlier settlement version, determining that Sackler family members would have inappropriately gained personal lawsuit protection through the corporate bankruptcy proceedings. The final agreement allows groups that decline payments to pursue legal action against family members.
A 2019 audit revealed that Sackler family members collected $10.8 billion from Purdue between 2008 and 2018, with no distributions received since that time. Nearly half of those funds went toward taxes the Sacklers paid on the company’s behalf. Congressional analysis in 2021 estimated the family’s combined net worth at $11 billion.
The settlement requires the release of 30 million company documents to the public. Similar to other opioid industry materials, these records will be housed at the University of California San Francisco and Johns Hopkins University.
Individuals who can demonstrate harm from prescribed Purdue opioids may receive up to $48,000 in compensation, along with survivors of those affected. Other major industry settlements do not provide direct payments to victims.
